TY - JOUR
T1 - Phosphodiesterase 5 inhibition in heart failure
T2 - Mechanisms and clinical implications
AU - Kumar, Praneet
AU - Francis, Gary S.
AU - Wilson Tang, W. H.
PY - 2009/5
Y1 - 2009/5
N2 - Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.
AB - Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.
UR - http://www.scopus.com/inward/record.url?scp=67649566083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649566083&partnerID=8YFLogxK
U2 - 10.1038/nrcardio.2009.32
DO - 10.1038/nrcardio.2009.32
M3 - Review article
C2 - 19377497
AN - SCOPUS:67649566083
SN - 1759-5002
VL - 6
SP - 349
EP - 355
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
IS - 5
ER -
